|
**Overview**: HIV-2 RNA Quantitative Panel**Introduction**: The HIV-2 RNA Quantitative Panel is a diagnostic tool designed to quantify HIV-2 viral load using whole blood samples. In India, HIV-2 infection is rare (~1-2 percent of HIV cases, higher in western/southern states), with slower progression but resistance to some ART (NNRTIs). Viral load monitoring is essential for confirming active infection and treatment response. High morbidity from under-testing in regions with dual HIV-1/2 prevalence, limited HIV-2 specific labs, delayed appropriate ART leading to virologic failure. Per microbiology practices aligned with NACO and WHO guidelines, the test employs PCR for HIV-2 RNA quantitative over 1-2 days with high accuracy, valuable for monitoring in HIV-2 mono or dual infection. This diagnostic falls under viral load monitoring and targets patients with HIV-2 diagnosis or risk, addressing accurate detection to guide protease inhibitor-based therapy. With elevated morbidity due to under-monitoring, the test supports public health efforts by enabling precise viremia assessment and reducing HIV-2 complications. Its whole blood-based approach ensures reliable viral load quantification.**Other Names**: HIV-2 RNA Pnl.**FDA Status**: FDA approved, CLIA certified for microbiology/immunology/hematology, compliant with 2025 standards.**Historical Milestone**: HIV-2 RNA quantitative; in India, used in high-prevalence areas.**Purpose**: The test assesses 3 parameters including HIV-2 RNA quantitative to guide viral load monitoring, assess active infection, inform therapy.**Test Parameters**: 1. HIV-2 RNA Quantitative, 2. Viral Load, 3. Total Lymphocytes.**Pretest Condition**: No fasting required; patients should have confirmed HIV-2.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell/RNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable for flow; RNA stable frozen.**Medical History**: Patients should provide details on HIV-2 diagnosis, treatment, symptoms.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of poor monitoring including progression, benefits of assessment, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low viral load can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Detectable viral load indicates active replication, necessitating specialist input.**Specialist Consultation**: HIV specialists should be consulted for management.**Additional Supporting Tests**: HIV-1/2 differentiation for confirmation.**Test Limitations**: HIV-2 specific; comprehensive approach required.**References**: Indian Journal of Medical Microbiology 2024, HIV Studies India 2023. |
